Skip to main content
Clinical Trials/ACTRN12613000751774
ACTRN12613000751774Not yet recruitingPhase 4

In children with inflammatory bowel disease and iron deficiency, does intravenous iron therapy with Ferric Carboxymaltose signficantly improve cognitive function, quality of life and iron status.

Gastroenterology Department, Royal Children's Hospital - Brisbane0 sites50 target enrollmentStarted: July 5, 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment

Eligibility Criteria

Ages
6 Years to 18 Years (—)
Sex
All

Inclusion Criteria

  • Paediatric patients with documented inflammatory bowel disease (Crohn's disease or Ulcerative colitis) being treated at the Royal Children's Hospital, with iron deficiency as defined by international criteria (ferritin less than 30, TS less than 16% or ferritin less than 100 with coexisting inflammation)

Exclusion Criteria

  • Patients will be excluded if:
  • 1 - They have a haemoglobinopathy
  • 2 - They received a blood transfusion in the previous 6 weeks
  • 3 - Patient or family do not give consent for participation in the study
  • 4 - They have advanced liver disease
  • 5 - They have acute severe colitis

Investigators

Sponsor
Gastroenterology Department, Royal Children's Hospital - Brisbane

Similar Trials